Text Version
RSS Feeds
Newsletter
Home Forum Photos Features Newsletter Archive Employment
About US Help Site Map
SEARCH   About US FAQ Site Map Site News
  SERVICES
  -Text Version
  -RSS Feeds
  -Newsletter
  -News Archive
  -Give us feedback
  -Voices of Readers
  -Online community
  -China Biz info
  What's new
 -
 -
China's drug watchdog allocates materials to help hemophilia treatments
+ -
13:15, December 16, 2007

 Related News
 19 missing after boat capsized in E China Sea
 Two killed, eight injured in pipeline explosion in north China
 Salvage workers drain corrosive chemicals from half-sunken ship on Yangtze River
 Shanghai to launch int'l channel targeting foreigners
 Chongqing Party chief meets WB president, calls for greater cooperation
 Comment  Tell A Friend
 Print Format  Save Article
China's drug authority has decided to allocate raw materials to clotting factor VIII producers to ease a nationwide shortage of the factor, which is a plasma-derived protein and a main treatment for hemophilia.

The State Food and Drug Administration (SFDA) said in a notice that the administration has asked four blood products companies based in Shanghai, Shandong, Henan and Guiyang to supply cryoprecipitate to the country's three clotting factor VIII producers as raw materials.

In China, three pharmaceutical manufacturers produce clotting factor VIII: Shanghai RAAS Blood Products Co., the Anhui-based Green Cross China Biotheological Co. and Hualan Biological Engineering in Henan Province.

Cryoprecipitate is a frozen blood product prepared from plasma.

To ensure safety of the products, the administration asked relevant companies to sign agreements to set down supply procedures, prices and transportation means, and submitted relevant documents to local food and drug agencies.

According to the SFDA, China has suffered from a shortage of clotting factor VIII in major cities and hospitals since August this year.

The total production of factor VIII in 2006 was 48.9 million units, while production so far this year has been only 33.4 million units, and two million more units are expected to be on the market by the year-end.

The SFDA's spokeswoman Yan Jiangying said earlier this week that it indicated "a 32-percent decrease year-on-year."

Yan said a shortage of plasma supply is the main cause of the problem, noting that most of factor VIII is extracted from blood plasma.

Plasma supply in China dropped by about 50 percent in 2006 from the previous year, said Yan, which in turn led to the lower production of factor VIII by Chinese blood product companies.

Hemophilia is a genetic disease. Patients suffer from low levels of plasma clotting factors. They are vulnerable to injuries: once a hemophiliac starts to bleed, there is no way to stop the bleeding except by an injection of the missing clotting factor.

Source: Xinhua



  Your Message:   Most Commented:
Readers Pick: Similar poses by babies and cats
World celebrities on China's peaceful rise, a harmonious world

|About Peopledaily.com.cn | Advertise on site | Contact us | Site map | Job offer|
Copyright by People's Daily Online, All Rights Reserved

http://english.people.com.cn/90001/90776/6321598.pdf